Yesterday it was reported that the EC of Five Prime Therapeutics (FPRX), Lewis Williams, exercised options to buy 91,217 FPRX shares at $4.56 a share, for a total transaction value of $415.9K.
This recent transaction increases Lewis Williams’ holding in the company by 24.38% to a total of $5.24 million.
See today’s analyst top recommended stocks >>
Currently, Five Prime Therapeutics has an average volume of 219.4K.
The insider sentiment on Five Prime Therapeutics has been positive according to 43 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150.
